DK175842B1 - Prostaglandinderivater til behandling af glaukom eller foröget okulært tryk - Google Patents
Prostaglandinderivater til behandling af glaukom eller foröget okulært tryk Download PDFInfo
- Publication number
- DK175842B1 DK175842B1 DK199001121A DK112190A DK175842B1 DK 175842 B1 DK175842 B1 DK 175842B1 DK 199001121 A DK199001121 A DK 199001121A DK 112190 A DK112190 A DK 112190A DK 175842 B1 DK175842 B1 DK 175842B1
- Authority
- DK
- Denmark
- Prior art keywords
- phenyl
- trinor
- prostaglandin derivative
- groups
- group
- Prior art date
Links
- 150000003180 prostaglandins Chemical class 0.000 title claims abstract description 49
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- 208000010412 Glaucoma Diseases 0.000 title claims description 17
- 230000004410 intraocular pressure Effects 0.000 claims description 34
- -1 isopropyl ester Chemical class 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- 150000001721 carbon Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 7
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 3
- 239000003732 agents acting on the eye Substances 0.000 claims description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 229940125702 ophthalmic agent Drugs 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000006413 ring segment Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 229930192474 thiophene Natural products 0.000 claims description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 9
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 210000001508 eye Anatomy 0.000 description 30
- 230000000694 effects Effects 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 18
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 8
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 7
- 241000282326 Felis catus Species 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 206010020565 Hyperaemia Diseases 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 206010015946 Eye irritation Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 231100000013 eye irritation Toxicity 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 101150041968 CDC13 gene Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000000622 irritating effect Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 206010052130 Episcleral hyperaemia Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 101100310593 Candida albicans (strain SC5314 / ATCC MYA-2876) SOD4 gene Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KUGRPPRAQNPSQD-UHFFFAOYSA-N OOOOO Chemical compound OOOOO KUGRPPRAQNPSQD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- MYHXHCUNDDAEOZ-UHFFFAOYSA-N Prostaglandin A&2% Natural products CCCCCC(O)C=CC1C=CC(=O)C1CC=CCCCC(O)=O MYHXHCUNDDAEOZ-UHFFFAOYSA-N 0.000 description 2
- 101100190148 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PGA2 gene Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000003733 optic disk Anatomy 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- MYHXHCUNDDAEOZ-FOSBLDSVSA-N prostaglandin A2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O MYHXHCUNDDAEOZ-FOSBLDSVSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101100219382 Caenorhabditis elegans cah-2 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 206010067013 Normal tension glaucoma Diseases 0.000 description 1
- STJFYCWYHROASW-UHFFFAOYSA-N O-methyl-glaucamine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C4OCOC4=CC=C3C12 STJFYCWYHROASW-UHFFFAOYSA-N 0.000 description 1
- NRPSBKVPXQFPBT-UHFFFAOYSA-N OP(OCC(CCC1=CC=CC=C1)=O)=O Chemical compound OP(OCC(CCC1=CC=CC=C1)=O)=O NRPSBKVPXQFPBT-UHFFFAOYSA-N 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001361 allenes Chemical class 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- NBEMQPLNBYYUAZ-UHFFFAOYSA-N ethyl acetate;propan-2-one Chemical compound CC(C)=O.CCOC(C)=O NBEMQPLNBYYUAZ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 201000002978 low tension glaucoma Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- 150000003163 prostaglandin D2 derivatives Chemical class 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- KPZSTOVTJYRDIO-UHFFFAOYSA-K trichlorocerium;heptahydrate Chemical compound O.O.O.O.O.O.O.Cl[Ce](Cl)Cl KPZSTOVTJYRDIO-UHFFFAOYSA-K 0.000 description 1
- 108700043117 vasectrin I Proteins 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK200401645A DK176053B1 (da) | 1988-09-06 | 2004-10-27 | Prostaglandinderivater til behandling af glaukom eller foröget okulært tryk |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8803110 | 1988-09-06 | ||
| SE8803110A SE8803110D0 (sv) | 1988-09-06 | 1988-09-06 | Prostaglandinderivat for behandling av glaukom eller okuler hypertension |
| SE8803855 | 1988-10-28 | ||
| SE8803855 | 1988-10-28 | ||
| SE8900475 | 1989-02-13 | ||
| PCT/SE1989/000475 WO1990002553A1 (en) | 1988-09-06 | 1989-09-06 | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK112190A DK112190A (da) | 1990-05-04 |
| DK112190D0 DK112190D0 (da) | 1990-05-04 |
| DK175842B1 true DK175842B1 (da) | 2005-03-29 |
Family
ID=26660291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK199001121A DK175842B1 (da) | 1988-09-06 | 1990-05-04 | Prostaglandinderivater til behandling af glaukom eller foröget okulært tryk |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US5422368A (es) |
| EP (6) | EP0569046B1 (es) |
| JP (3) | JP2721414B2 (es) |
| AT (3) | ATE227576T1 (es) |
| DE (5) | DE68929563D1 (es) |
| DK (1) | DK175842B1 (es) |
| ES (5) | ES2186670T3 (es) |
| FI (1) | FI92690C (es) |
| HK (2) | HK1048106A1 (es) |
| HU (1) | HU211593A9 (es) |
| LU (1) | LU91541I2 (es) |
| NL (1) | NL970039I2 (es) |
| WO (1) | WO1990002553A1 (es) |
Families Citing this family (253)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420422B1 (en) | 1987-09-18 | 2002-07-16 | Sucampo Pharmaceuticals, Inc. | Ocular hypotensive agents |
| US5166178B1 (en) * | 1987-09-18 | 1998-07-21 | R Tech Ueno Ltd | Ocular hypotensive agents |
| US5151444B1 (en) * | 1987-09-18 | 1999-07-06 | R Tech Ueno Ltd | Ocular hypotensive agents |
| US5236907A (en) * | 1988-10-01 | 1993-08-17 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
| US5212200A (en) * | 1987-09-18 | 1993-05-18 | R-Tech Ueno, Ltd. | Ocular hypotensive agents |
| US5565492A (en) * | 1988-07-18 | 1996-10-15 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5321128A (en) * | 1988-09-06 | 1994-06-14 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| JP2721414B2 (ja) * | 1988-09-06 | 1998-03-04 | フアーマシア・アンド・アツプジヨン・アー・ベー | 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体 |
| US6187813B1 (en) | 1990-04-10 | 2001-02-13 | Pharmacia & Upjohn Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5194429A (en) * | 1988-10-01 | 1993-03-16 | K.K. Ueno Seiyaku Oyo Kenkyujo | Ocular hypotensive agents |
| HU212570B (en) * | 1991-06-24 | 1996-08-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester |
| US5223537A (en) * | 1991-07-23 | 1993-06-29 | Kabi Pharmacia Ab | Method and composition for treatment of gastric and duodenal disorders |
| US5688819A (en) * | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US6602900B2 (en) * | 1992-09-21 | 2003-08-05 | Allergan, Inc. | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5834498A (en) * | 1992-09-21 | 1998-11-10 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5352708A (en) * | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5972991A (en) * | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5468778A (en) * | 1992-09-24 | 1995-11-21 | Allergan, Inc. | Method of lowering intraocular pressure by administering a pharmaceutical composition containing 7-(5-substituted cyclopentyl) and 7-(5-substituted-cyclopentenyl) 5-heptenoic acids and derivatives |
| ATE153855T1 (de) * | 1992-10-13 | 1997-06-15 | Alcon Lab Inc | Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten |
| US5332730A (en) * | 1992-10-16 | 1994-07-26 | Allergan, Inc. | Azido derivatives of cyclopentane heptanoic or heptenoic acid |
| US5385945A (en) * | 1992-10-21 | 1995-01-31 | Allergan, Inc. | 7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds |
| US5328933A (en) * | 1992-10-28 | 1994-07-12 | Allergan, Inc. | Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues |
| US5312842A (en) * | 1992-10-30 | 1994-05-17 | Allergan, Inc. | Cyclopentane heptenylsulfinylalkyl and heptanylsulfinylalkyl-2-aliphatic or aryl aliphatic derivatives |
| US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US6184250B1 (en) * | 1993-08-03 | 2001-02-06 | Alcon Laboratories, Inc. | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
| US5387608A (en) * | 1993-08-17 | 1995-02-07 | Allergan, Inc. | Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents |
| US5476872A (en) * | 1993-10-18 | 1995-12-19 | Allergan, Inc. | 1,11-diesters of prostaglandin-F2α having a polar ester group at C-1 |
| US5486540A (en) * | 1993-10-28 | 1996-01-23 | Allergan, Inc. | Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents |
| US5627209A (en) * | 1993-12-15 | 1997-05-06 | Alcon Laboratories, Inc. | Use of certain 9-haloprostaglandins to treat glaucoma and ocular hypertension |
| US5721273A (en) | 1993-12-15 | 1998-02-24 | Alcon Laboratories, Inc. | Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension |
| US5416106A (en) * | 1993-12-28 | 1995-05-16 | Allergan, Inc. | 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof |
| US6462077B1 (en) | 1993-12-28 | 2002-10-08 | Allergan, Inc. | Thromboxane ligands without blood clotting side effects |
| US5741812A (en) * | 1993-12-28 | 1998-04-21 | Allergan | Thromboxane ligands without blood clotting side effects |
| US5650431A (en) * | 1993-12-28 | 1997-07-22 | Allergan | Thromboxane ligands without blood clotting side effects |
| US5545665A (en) | 1993-12-28 | 1996-08-13 | Allergan | Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents |
| US5462968A (en) * | 1994-01-19 | 1995-10-31 | Allergan, Inc. | EP2 -receptor agonists as agents for lowering intraocular pressure |
| US5516796A (en) * | 1994-03-24 | 1996-05-14 | Kabi Pharmacia Ab | Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof |
| SE9401087D0 (sv) * | 1994-03-31 | 1994-03-31 | Pharmacia Ab | New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| SE9403158D0 (sv) * | 1994-09-21 | 1994-09-21 | Pharmacia Ab | New use of prostaglandins |
| US5807892A (en) * | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
| US5698733A (en) * | 1994-09-30 | 1997-12-16 | Alcon Laboratories, Inc. | Use of 9-deoxy prostaglandin derivatives to treat glaucoma |
| US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| CA2221110C (en) * | 1995-05-18 | 2009-08-04 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension |
| US6169111B1 (en) | 1995-06-07 | 2001-01-02 | Alcon Laboratories, Inc. | Conformationally rigid aryl prostaglandins for use in glaucoma therapy |
| US5698598A (en) * | 1995-08-04 | 1997-12-16 | Allergan | EP2 -receptor agonists as agents for lowering intraocular pressure |
| US5700835A (en) * | 1995-12-22 | 1997-12-23 | Alcon Laboratories, Inc. | 3-Oxa-D-prostaglandins for lowering IOP |
| WO1997023225A1 (en) * | 1995-12-22 | 1997-07-03 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
| US5658897A (en) * | 1996-04-08 | 1997-08-19 | Allergan | Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents |
| DE69714274T3 (de) † | 1996-09-17 | 2006-06-01 | Asahi Glass Co., Ltd. | Fluorierte prostaglandinderivate und medikamente |
| KR20000053228A (ko) | 1996-11-12 | 2000-08-25 | 제임스 에이. 아노 | 안압강하제로서의 프로스타글란딘의 시스-δ⁴ 유사체 |
| AU5436198A (en) * | 1996-11-12 | 1998-06-03 | Alcon Laboratories, Inc. | 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension |
| DE69823852T2 (de) | 1997-02-04 | 2005-05-19 | Johnstone, Murray A., Seattle | Verfahren zur förderung des haarwuchses und entwicklung des haarsystems |
| AU6545498A (en) | 1997-03-07 | 1998-09-22 | Alcon Laboratories, Inc. | 13-thia prostaglandins for use in glaucoma therapy |
| US6770675B2 (en) | 1997-03-17 | 2004-08-03 | Novartis Ag | Compositions and methods for reducing ocular hypertension |
| CA2293325C (en) * | 1997-05-09 | 2008-09-02 | The Mount Sinai School Of Medicine Of The City University Of New York | 8-iso-prostaglandins for glaucoma therapy |
| TR200000671T2 (tr) * | 1997-09-09 | 2000-07-21 | The Procter & Gamble Company | FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler. |
| SK3382000A3 (en) * | 1997-09-09 | 2000-10-09 | Procter & Gamble | A compound having structure of aromatic substituted prostaglandins and its use for the treatment of bone disorders |
| WO1999018969A1 (fr) * | 1997-10-13 | 1999-04-22 | R-Tech Ueno, Ltd. | Composition curative de l'hypertension intraoculaire ou du glaucome |
| WO1999018970A1 (fr) * | 1997-10-14 | 1999-04-22 | Senju Pharmaceutical Co., Ltd. | Medicaments a action preventive et remedes contre les troubles circulatoires ophtalmiques |
| US6066671A (en) | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
| US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| US6441033B1 (en) | 1997-12-22 | 2002-08-27 | Alcon Manufacturing, Ltd. | 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists |
| US6492417B1 (en) | 1997-12-22 | 2002-12-10 | Alcon Manufacturing, Ltd. | 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists |
| ID26699A (id) | 1998-03-31 | 2001-02-01 | Procter & Gamble | Prostaglandin c11 oksimil dan hidroksilamino yang berguna sebagai obat |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6160013A (en) * | 1998-12-17 | 2000-12-12 | Alcon Laboratories, Inc. | 14-aza prostaglandins for the treatment of glaucoma and ocular hypertension |
| SE9900672D0 (sv) * | 1999-02-25 | 1999-02-25 | Synphora Ab | Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula |
| NZ513825A (en) | 1999-03-05 | 2001-09-28 | Procter & Gamble | C 16 unsaturated FP-selective prostaglandins analogs |
| US6894175B1 (en) * | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
| TWI290470B (en) | 1999-12-01 | 2007-12-01 | Sankyo Co | The composition for treating glaucoma |
| CN100506232C (zh) * | 2000-03-16 | 2009-07-01 | 苏坎波公司 | 用于治疗眼压过高和青光眼的组合物 |
| US6458836B1 (en) | 2000-03-16 | 2002-10-01 | Sucampo, A.G. | Treatment of ocular hypertension and glaucoma |
| US7005443B1 (en) | 2000-03-17 | 2006-02-28 | Alcon, Inc. | 5-Hydroxy indazole derivatives for treating glaucoma |
| US6927233B1 (en) | 2000-03-17 | 2005-08-09 | Alcon, Inc. | 5ht2 agonists for controlling IOP and treating glaucoma |
| US20030119846A1 (en) * | 2000-03-17 | 2003-06-26 | Collier Jr Robert J. | Compounds with 5-ht activity useful for controlling visual field loss |
| US6806285B1 (en) | 2000-03-17 | 2004-10-19 | Alcon, Inc. | 5-Hydroxyl indole derivatives for treating glaucoma |
| US6956036B1 (en) | 2000-03-17 | 2005-10-18 | Alcon, Inc. | 6-hydroxy-indazole derivatives for treating glaucoma |
| US7012090B1 (en) | 2000-03-17 | 2006-03-14 | Alcon, Inc. | Pyranoindoles for treating glaucoma |
| AU2001219185A1 (en) | 2000-03-17 | 2001-10-03 | Alcon, Inc. | 2-acylaminobenzimidazole derivatives for treating glaucoma |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US20020037914A1 (en) * | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
| US20020146439A1 (en) * | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
| US20020172693A1 (en) * | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| WO2001087816A1 (en) * | 2000-05-15 | 2001-11-22 | Pharmacia & Upjohn Company | Process and intermediates to prepare latanoprost |
| GB0012249D0 (en) * | 2000-05-19 | 2000-07-12 | Chirotech Technology Ltd | Process for the preparation of 11-oxaprostaglandins |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| US20020035148A1 (en) * | 2000-07-20 | 2002-03-21 | Ryuji Ueno | Treatment of ocular hypertension |
| US6376533B1 (en) * | 2000-10-20 | 2002-04-23 | Allergan Sales, Inc. | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| US6586462B2 (en) | 2000-10-20 | 2003-07-01 | Allergan, Inc. | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| WO2004098807A1 (en) * | 2000-11-21 | 2004-11-18 | Barsplice Products, Inc. | Method of making steel couplers for joining concrete reinforcing bars |
| US6699493B2 (en) | 2000-11-29 | 2004-03-02 | Oculex Pharmaceuticals, Inc. | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| CA2443937A1 (en) * | 2001-04-23 | 2002-10-31 | Randall D. Glickman | Prostanoids augment ocular drug penetration |
| KR100437873B1 (ko) * | 2001-05-08 | 2004-06-26 | 연성정밀화학(주) | 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질 |
| US20030212107A1 (en) * | 2001-05-10 | 2003-11-13 | Kapin Michael A. | R-reliprodil for treating glaucoma |
| GB0112699D0 (en) * | 2001-05-24 | 2001-07-18 | Resolution Chemicals Ltd | Process for the preparation of prostglandins and analogues thereof |
| TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
| MXPA03010807A (es) * | 2001-06-01 | 2004-11-22 | Alcon Inc | Piranoidazoles y su uso para el tratamiento del glaucoma. |
| CA2447479A1 (en) * | 2001-06-01 | 2002-12-12 | Alcon, Inc. | Novel arylaminopropane analogues and their use for the treatment of glaucoma |
| CA2447156A1 (en) * | 2001-06-01 | 2002-12-12 | Alcon, Inc. | Novel fused indazoles and indoles and their use for the treatment of glaucoma |
| US20030027853A1 (en) * | 2001-06-14 | 2003-02-06 | Allergan Sales, Inc. | 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| US7872045B2 (en) * | 2001-06-14 | 2011-01-18 | Allergan, Inc. | Combination therapy for glaucoma treatment |
| US20050222094A1 (en) * | 2001-06-14 | 2005-10-06 | Burk Robert M | Treatment of inflammatory bowel disease |
| US6713268B2 (en) * | 2001-06-26 | 2004-03-30 | Allergan, Inc. | Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation |
| US20030187071A1 (en) * | 2001-07-17 | 2003-10-02 | Henegar Kevin E. | Process and intermediates to prepare latanoprost |
| KR100581647B1 (ko) | 2001-07-17 | 2006-05-22 | 파마시아 앤드 업존 캄파니 엘엘씨 | 라타노프로스트 제조를 위한 방법 및 중간체 |
| CA2458230A1 (en) * | 2001-08-23 | 2003-03-06 | Sucampo Ag | Method and composition for treatment of ocular hypertension and glaucoma |
| US6884816B2 (en) | 2001-08-31 | 2005-04-26 | Alcon, Inc. | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma |
| US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
| TW200305424A (en) | 2002-01-29 | 2003-11-01 | Santen Pharmaceutical Co Ltd | Glaucoma-treating agent comprising bunazosin and prostaglandin |
| US8758733B2 (en) | 2002-02-04 | 2014-06-24 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US9216183B2 (en) | 2002-02-04 | 2015-12-22 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US7351404B2 (en) * | 2002-02-04 | 2008-04-01 | Allergan, Inc. | Method of enhancing hair growth |
| US20040110776A1 (en) * | 2002-02-22 | 2004-06-10 | Iok-Hou Pang | Use of propentofylline to control intraocular pressure |
| AU2003233729B2 (en) | 2002-06-06 | 2007-10-04 | Merck Frosst Canada Ltd | 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma |
| JP2005534653A (ja) * | 2002-06-06 | 2005-11-17 | メルク フロスト カナダ アンド カンパニー | 眼及び骨疾患の治療に於いてｅｐ４受容体作動薬として使用するための１，５−二置換イミダゾリジン−２−オン誘導体 |
| US6864282B2 (en) | 2002-08-05 | 2005-03-08 | Allergan, Inc. | 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| WO2005018646A1 (ja) * | 2003-08-21 | 2005-03-03 | Sucampo Ag | 眼科用組成物 |
| US20040076678A1 (en) * | 2002-08-21 | 2004-04-22 | Sucampo Ag | Opthalmic solution |
| US8580851B2 (en) | 2002-08-21 | 2013-11-12 | Sucampo Ag | Ophthalmic solution |
| EP1545517A1 (en) * | 2002-08-28 | 2005-06-29 | Merck Frosst Canada & Co. | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma |
| EP2314299A1 (en) * | 2002-08-29 | 2011-04-27 | Santen Pharmaceutical Co., Ltd | Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin |
| PL375564A1 (en) * | 2002-08-30 | 2005-11-28 | Alcon, Inc. | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma |
| CA2707067C (en) | 2002-09-09 | 2013-07-16 | Santen Pharmaceutical Co., Ltd. | Clear ophthalmic solution comprising latanoprost as active ingredient |
| US7074827B2 (en) * | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
| JP2006505572A (ja) * | 2002-10-25 | 2006-02-16 | メルク フロスト カナダ アンド カンパニー | Ｅｐ４受容体アゴニストとしての２−ピロリドン |
| US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| JP2006510742A (ja) * | 2002-11-08 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 高眼圧治療用眼科組成物 |
| KR20050074547A (ko) * | 2002-11-12 | 2005-07-18 | 알콘, 인코퍼레이티드 | 눈의 퇴행성 질환을 치료하기 위한 히스톤 디아세틸라제저해제 |
| US20080004311A1 (en) * | 2002-11-12 | 2008-01-03 | Alcon, Inc. | Histone deacetylase inhibitors for treating degenerative diseases of the eye |
| KR101223886B1 (ko) | 2002-11-18 | 2013-01-17 | 산텐 세이야꾸 가부시키가이샤 | Ｒｈｏ 키나아제 억제제와 β 차단약으로 이루어진 녹내장 치료제 |
| US7053085B2 (en) * | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| CA2506204A1 (en) * | 2002-12-13 | 2004-07-01 | Alcon, Inc. | Novel benzopyran analogs and their use for the treatment of glaucoma |
| US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US20040225014A1 (en) * | 2003-02-14 | 2004-11-11 | Sucampo Ag | Method for treating ocular hypertension and glaucoma |
| CA2530081A1 (en) * | 2003-07-01 | 2005-01-13 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| US20050119262A1 (en) * | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
| JP2007504228A (ja) * | 2003-09-02 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼組成物 |
| EP1663221A4 (en) * | 2003-09-04 | 2009-04-22 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION |
| WO2005026128A1 (en) * | 2003-09-04 | 2005-03-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| US20050058730A1 (en) * | 2003-09-15 | 2005-03-17 | Xushan Wan | Compositions and methods for preventing or treating eyestrain |
| AU2004285486A1 (en) * | 2003-10-22 | 2005-05-12 | University Of Rochester | Use of peroxisome proliferator-activated receptor gamma (PPARgamma) and/or retinoic acid receptor (RXR) agonists to inhibit platelet functions |
| ES2331313T3 (es) | 2003-11-07 | 2009-12-29 | Senju Pharmaceutical Co., Ltd. | Composicion farmaceutica que contiene prostaglandina. |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US7476687B2 (en) * | 2003-11-26 | 2009-01-13 | Alcon, Inc. | Substituted furo[2,3-g]indazoles for the treatment of glaucoma |
| US7338972B1 (en) | 2003-12-15 | 2008-03-04 | Alcon, Inc. | Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma |
| WO2005058911A2 (en) * | 2003-12-15 | 2005-06-30 | Alcon, Inc. | Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma |
| US7129257B1 (en) * | 2003-12-15 | 2006-10-31 | Alcon, Inc. | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma |
| EP3002277B1 (en) | 2004-01-05 | 2019-11-06 | Nicox S.A. | Prostaglandin derivatives |
| EP1706095B1 (en) | 2004-01-20 | 2008-12-24 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| ATE404189T1 (de) * | 2004-04-26 | 2008-08-15 | Alcon Inc | Statine zur behandlung von okularer hypertonie und glaukom |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US20050244458A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US8591885B2 (en) | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
| US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| BRPI0510485A (pt) | 2004-04-30 | 2007-11-13 | Allergan Inc | implantes inibidores de tirosina cinase intravìtreos biodegradáveis |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| JP2008507521A (ja) | 2004-07-20 | 2008-03-13 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼科用組成物 |
| US7183310B2 (en) * | 2004-08-10 | 2007-02-27 | Allergan, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| SE0402029D0 (sv) * | 2004-08-17 | 2004-08-17 | Synphora Ab | Prostaglandin a derivatieves for the treatment of psoriasis |
| US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
| US8541413B2 (en) * | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| US20070293558A1 (en) * | 2004-10-13 | 2007-12-20 | Ying-Duo Gao | Ophthalmic Compositions for Treating Ocular Hypertension |
| US20080097108A1 (en) * | 2004-10-13 | 2008-04-24 | Ying-Duo Gao | Ophthalmic Compositions for Treating Ocular Hypertension |
| US7425572B2 (en) * | 2004-12-08 | 2008-09-16 | Alcon, Inc. | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma |
| US7851504B2 (en) | 2005-03-16 | 2010-12-14 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
| US9241918B2 (en) | 2005-03-16 | 2016-01-26 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
| PT1864666E (pt) | 2005-03-31 | 2012-09-06 | Santen Pharmaceutical Co Ltd | Agente protector para célula neuronal retiniana contendo derivado de prostaglandina f2 alfa como ingrediente activo |
| WO2006112313A1 (ja) | 2005-04-13 | 2006-10-26 | Ube Industries, Ltd. | インダゾール誘導体を有効成分として含む網膜神経細胞保護剤 |
| WO2007002670A2 (en) * | 2005-06-28 | 2007-01-04 | Bausch & Lomb Incorporated | Method of lowering intraocular pressure |
| CA2613748A1 (en) * | 2005-06-29 | 2007-01-04 | Pfizer Inc. | Prostaglandin derivatives |
| JP2009502982A (ja) * | 2005-08-03 | 2009-01-29 | メルク フロスト カナダ リミテツド | Ｅｐ４受容体アゴニスト、この組成物および方法 |
| TW200744567A (en) * | 2005-09-23 | 2007-12-16 | Alcon Inc | Phenylethylamine analogs and their use for treating glaucoma |
| US7863318B2 (en) | 2005-11-03 | 2011-01-04 | Allergan, Inc. | Prostaglandins and analogues as agents for lowering intraocular pressure |
| EP2004193A2 (en) * | 2006-03-13 | 2008-12-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| WO2007111806A2 (en) * | 2006-03-23 | 2007-10-04 | Massachusetts Eye And Ear Infirmary | Cyclopentane heptanoic acid compounds for reducing body fat |
| CA2653903A1 (en) * | 2006-06-12 | 2007-12-21 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US7642370B2 (en) | 2006-08-07 | 2010-01-05 | Daiichi Fine Chemical Co., Ltd. | Method for preparing prostaglandin derivative |
| CA2665081C (en) | 2006-10-02 | 2015-12-01 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates |
| CN101511774B (zh) | 2006-10-03 | 2015-05-13 | 于崇曦 | 具有快速皮肤穿透速度的带正电荷的水溶性的芥子气类化合物及其相关化合物的前药 |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| UY30883A1 (es) | 2007-01-31 | 2008-05-31 | Alcon Res | Tapones punctales y metodos de liberacion de agentes terapeuticos |
| EP2123278B1 (en) | 2007-02-07 | 2013-01-09 | Teika Pharmaceutical Co., Ltd. | Eye drop preparation comprising latanoprost |
| US20090018204A1 (en) * | 2007-07-13 | 2009-01-15 | Brinkenhoff Michael C | Composition and method for enhancing hair growth |
| US20090170944A1 (en) * | 2008-01-02 | 2009-07-02 | Novagali Pharma Sa | Ophthalmic micellar compositions with enhanced stability |
| EP2077104A1 (en) | 2008-01-02 | 2009-07-08 | Novagali Pharma SA | Micellar compositions with ophtalmic applications |
| EP2077105A1 (en) | 2008-01-02 | 2009-07-08 | Novagali Pharma SA | Ophthalmic Micellar Compositions with Enhanced Stability |
| US20090169629A1 (en) * | 2008-01-02 | 2009-07-02 | Novagali Pharma Sa | Micellar compositions with ophthalmic applications |
| EP2135860A1 (en) * | 2008-06-20 | 2009-12-23 | Sandoz AG | Improved process for the production of bimatoprost |
| EP2143712A1 (en) * | 2008-07-10 | 2010-01-13 | Sandoz AG | Improved Process for the Production of Prostaglandins and Prostaglandin Analogs |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| EP2349242B1 (en) | 2008-10-29 | 2018-12-05 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| US8623918B2 (en) * | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| US20100204335A1 (en) * | 2008-12-01 | 2010-08-12 | Allergan, Inc. | Kit and composition for eyelash growth |
| IT1392492B1 (it) | 2008-12-24 | 2012-03-09 | Ind Chimica Srl | Processo per la purificazione del latanoprost, analogo sintetico della prostaglandina pgf2alfa. |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| WO2010112615A1 (en) | 2009-04-03 | 2010-10-07 | Dsm Ip Assets B.V. | Lysine derivatives functionalised with lipids |
| US8394826B2 (en) | 2009-05-01 | 2013-03-12 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| EP2478906A4 (en) | 2009-09-17 | 2013-02-20 | Senju Pharma Co | AQUEOUS OPHTHALMIC DROPS THAT CONTAIN LATANOPROST, AND A METHOD OF INHIBITING ADSORPTION OF LATANOPROST ON A RESIN |
| NZ628266A (en) * | 2009-11-09 | 2016-02-26 | Allergan Inc | Compositions and methods for stimulating hair growth |
| US9149484B2 (en) | 2009-11-09 | 2015-10-06 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
| CN102711771B (zh) * | 2010-01-11 | 2016-05-18 | 伊诺泰克制药公司 | 降低眼压的组合、试剂盒和方法 |
| WO2011095990A2 (en) | 2010-02-03 | 2011-08-11 | Fdc Limited | Process for the purification of prostaglandins and analogues thereof |
| CN102933593A (zh) | 2010-03-26 | 2013-02-13 | 伊诺泰克制药公司 | 使用n6-环戊基腺苷（cpa）、cpa衍生物或其前药降低人眼内压的方法 |
| CN103052406A (zh) * | 2010-07-19 | 2013-04-17 | 印斯拜尔药品股份有限公司 | 双官能rho激酶抑制剂化合物、组合物及应用 |
| SI3431074T1 (sl) | 2010-07-29 | 2022-07-29 | Allergan, Inc. | Raztopine bimatoprosta in timolola brez konzervansov |
| US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| CN103079535B (zh) | 2010-08-02 | 2016-10-12 | Ac专利控股公司 | 用于增强毛发的组合物、方法和试剂盒 |
| BR112013014021A8 (pt) | 2010-12-06 | 2017-10-03 | Follica Inc | Métodos para tratamento de calvície e promoção de crescimento de cabelos |
| CA2866067C (en) | 2011-01-19 | 2015-04-21 | Topokine Therapeutics, Inc. | Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia |
| US8859616B2 (en) | 2011-01-21 | 2014-10-14 | Allergan, Inc. | Compounds and methods for enhancing hair growth |
| ES2684351T3 (es) | 2011-02-04 | 2018-10-02 | Kowa Co., Ltd. | Terapia farmacológica para prevenir o tratar glaucoma |
| EP2495235B1 (en) | 2011-03-04 | 2015-08-05 | Newchem S.p.A. | Process for the synthesis of prostaglandins and intermediates thereof |
| CN102690219A (zh) * | 2011-03-24 | 2012-09-26 | 天津信汇制药股份有限公司 | 纯化贝美前列素的方法 |
| WO2012149287A1 (en) | 2011-04-29 | 2012-11-01 | Allergan, Inc. | Solvent cast film sustained release latanoprost implant |
| CN106349138A (zh) * | 2011-06-02 | 2017-01-25 | 奇诺因私人有限公司 | 用于制备前列腺素酰胺的新的方法 |
| US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
| EA027109B1 (ru) | 2012-01-26 | 2017-06-30 | Инотек Фармасьютикалс Корпорейшн | Безводные полиморфы [(2r,3s,4r,5r)-5-(6-(циклопентиламино)-9h-пурин-9-ил)-3,4-дигидрокситетрагидрофуран-2-ил]метилнитрата и способы их получения |
| EP2822927A1 (en) * | 2012-03-09 | 2015-01-14 | Instytut Farmaceutyczny | PROCESS FOR PREPARATION OF PROSTAGLANDIN F2alpha ANALOGUES |
| CA2869676C (en) | 2012-11-21 | 2015-06-23 | Topokine Therapeutics, Inc. | Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat |
| US9120738B2 (en) | 2012-12-28 | 2015-09-01 | Allergan, Inc. | Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof |
| AU2014216112B2 (en) | 2013-02-15 | 2019-02-21 | Allergan, Inc. | Sustained drug delivery implant |
| MX2015013234A (es) | 2013-03-15 | 2016-04-15 | Inotek Pharmaceuticals Corp | Formulaciones oftalmicas. |
| EP3811943B1 (en) | 2013-03-15 | 2023-02-22 | Aerie Pharmaceuticals, Inc. | Compound for use in the treatment of ocular disorders |
| NO2753788T3 (es) | 2013-05-10 | 2018-06-16 | ||
| US9820993B2 (en) | 2013-05-15 | 2017-11-21 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
| ITMI20132193A1 (it) * | 2013-12-23 | 2015-06-24 | Ind Chimica Srl | Processo microbiologico per la preparazione di intermedi utili nella sintesi di prostaglandine |
| HU231214B1 (hu) * | 2014-03-13 | 2021-11-29 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | Új eljárás nagytisztaságú prosztaglandinok előállítására |
| US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
| WO2016063184A1 (en) | 2014-10-20 | 2016-04-28 | Sentiss Pharma Private Limited | Ophthalmic solution |
| KR102511830B1 (ko) | 2014-11-25 | 2023-03-17 | 엑시모어 엘티디. | 단일 및 다수 생체활성제를 전달하기 위한 조성물 및 방법 |
| JP2018534018A (ja) | 2015-09-27 | 2018-11-22 | フォリカ, インコーポレーテッドFollica, Inc. | 針刺入装置及び薬物アプリケーター |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| BR112019003945A2 (pt) | 2016-08-31 | 2019-05-21 | Aerie Pharmaceuticals, Inc. | composições oftálmicas |
| CN110506037A (zh) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | 芳基环丙基-氨基-异喹啉酰胺化合物 |
| WO2020056345A1 (en) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| CN112142703A (zh) * | 2020-09-30 | 2020-12-29 | 东北制药集团股份有限公司 | 一种卡前列素氨丁三醇相关杂质左旋丁基15-酮及其制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1324737A (en) * | 1970-11-02 | 1973-07-25 | Upjohn Co | Prostaglandins and the preparation thereof |
| JPS4920766B1 (es) † | 1970-11-10 | 1974-05-27 | ||
| JPS4924911B1 (es) † | 1970-12-07 | 1974-06-26 | ||
| BE786251A (fr) * | 1971-07-14 | 1973-01-15 | Ici Ltd | Nouveaux derives du cyclopentane |
| US3987087A (en) * | 1971-07-29 | 1976-10-19 | The Upjohn Company | Phenyl-substituted prostaglandin-f type analogs |
| US4304907A (en) * | 1972-05-10 | 1981-12-08 | The Upjohn Company | Bicyclo lactone intermediates for prostaglandin analogs |
| US4011262A (en) * | 1972-07-13 | 1977-03-08 | Pfizer Inc. | 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series |
| US3956284A (en) * | 1972-07-13 | 1976-05-11 | Pfizer Inc. | Heterocyclic 15-substituted-ω-pentanorprostoglandins |
| US3962312A (en) * | 1972-09-21 | 1976-06-08 | Ono Pharmaceutical Company | 9,11,15-Trihydroxy prost-5-enoic acid analogues |
| JPS5720305B2 (es) * | 1973-02-28 | 1982-04-27 | ||
| IT1053781B (it) * | 1974-09-25 | 1981-10-10 | Erba C S P A Ora Farmitalia | Omega nor cicloalcil 13.14 deidro prostaglandine |
| US4001300A (en) * | 1975-02-24 | 1977-01-04 | The Upjohn Company | 2,2-Difluoro-16-phenoxy-PGF2 analogs |
| US4117119A (en) * | 1975-03-11 | 1978-09-26 | Ono Pharmaceutical Company | 15-cyclobutyl-prostaglandins |
| US4097489A (en) | 1977-06-17 | 1978-06-27 | The Upjohn Company | 9-Deoxy-9α,6-nitrilo or 6,9α-imino-PGF compounds |
| US4131738A (en) | 1977-07-05 | 1978-12-26 | The Upjohn Company | 6-Hydroxy-PGE1 compounds |
| US4115586A (en) * | 1977-07-18 | 1978-09-19 | The Upjohn Company | Antihyperthermic use for prostaglandins |
| US4128713A (en) * | 1977-12-15 | 1978-12-05 | The Upjohn Company | 6,7-Didehydro-PGI1 compounds |
| US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| US5057621A (en) * | 1984-07-31 | 1991-10-15 | Syntex (U.S.A.) Inc. | 11-substituted-16-phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives |
| ZA855740B (en) * | 1984-07-31 | 1987-03-25 | Syntex Inc | 11-substituted-16-phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives |
| DE3510978A1 (de) * | 1985-03-22 | 1986-09-25 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US4820728A (en) * | 1985-11-25 | 1989-04-11 | G. D. Searle & Co. | Tetraenyl prostaglandins |
| US4883819A (en) * | 1986-07-31 | 1989-11-28 | The Trustees Of Columbia University In The City Of New York | Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma |
| EP0242580B1 (en) * | 1986-03-13 | 1993-04-28 | The Trustees Of Columbia University In The City Of New York | Use of a, b and c prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma |
| DE3782836T2 (de) * | 1986-03-21 | 1993-04-01 | Shell Int Research | Schmelzdichtungsmasse. |
| US4824857A (en) * | 1986-05-16 | 1989-04-25 | Yasumasa Goh | Use of prostaglandin D2 -active substances |
| CA1322749C (en) * | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| CA1324129C (en) * | 1987-04-30 | 1993-11-09 | Ryuzo Ueno | Prostaglandins of the f series |
| US5151444B1 (en) * | 1987-09-18 | 1999-07-06 | R Tech Ueno Ltd | Ocular hypotensive agents |
| US5166178B1 (en) * | 1987-09-18 | 1998-07-21 | R Tech Ueno Ltd | Ocular hypotensive agents |
| JPH0739344B2 (ja) * | 1988-10-01 | 1995-05-01 | 株式会社アールテック・ウエノ | 眼圧降下剤 |
| JPH0739343B2 (ja) * | 1988-10-01 | 1995-05-01 | 株式会社アールテック・ウエノ | 眼圧降下剤 |
| ATE108330T1 (de) * | 1987-09-18 | 1994-07-15 | R Tech Ueno Ltd | Hypotensive okulare mittel. |
| JP2597629B2 (ja) * | 1988-02-26 | 1997-04-09 | 株式会社 上野製薬応用研究所 | １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化 |
| JP2721414B2 (ja) * | 1988-09-06 | 1998-03-04 | フアーマシア・アンド・アツプジヨン・アー・ベー | 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体 |
| EP0580268B1 (en) * | 1988-10-01 | 1998-01-14 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
| US5194429A (en) * | 1988-10-01 | 1993-03-16 | K.K. Ueno Seiyaku Oyo Kenkyujo | Ocular hypotensive agents |
-
1989
- 1989-09-06 JP JP1509228A patent/JP2721414B2/ja not_active Expired - Lifetime
- 1989-09-06 ES ES93109514T patent/ES2186670T3/es not_active Expired - Lifetime
- 1989-09-06 EP EP93109514A patent/EP0569046B1/en not_active Expired - Lifetime
- 1989-09-06 ES ES02009255.7T patent/ES2317964T5/es not_active Expired - Lifetime
- 1989-09-06 EP EP03014533A patent/EP1348437A3/en not_active Withdrawn
- 1989-09-06 DE DE68929563T patent/DE68929563D1/de not_active Expired - Lifetime
- 1989-09-06 DE DE68929435T patent/DE68929435T2/de not_active Expired - Lifetime
- 1989-09-06 AT AT93109514T patent/ATE227576T1/de not_active IP Right Cessation
- 1989-09-06 DE DE0001348437T patent/DE03014533T1/de active Pending
- 1989-09-06 ES ES89850294T patent/ES2062102T5/es not_active Expired - Lifetime
- 1989-09-06 EP EP02009257A patent/EP1224935A3/en not_active Withdrawn
- 1989-09-06 DE DE68913000T patent/DE68913000T3/de not_active Expired - Lifetime
- 1989-09-06 AT AT89850294T patent/ATE101342T1/de active
- 1989-09-06 WO PCT/SE1989/000475 patent/WO1990002553A1/en active IP Right Grant
- 1989-09-06 AT AT02009255T patent/ATE420857T1/de not_active IP Right Cessation
- 1989-09-06 ES ES03014533T patent/ES2213504T1/es active Pending
- 1989-09-06 ES ES03000517T patent/ES2193901T1/es active Pending
- 1989-09-06 EP EP89850294A patent/EP0364417B9/en not_active Expired - Lifetime
- 1989-09-06 DE DE1300150T patent/DE1300150T1/de active Pending
- 1989-09-06 EP EP02009256A patent/EP1224934A3/en not_active Withdrawn
- 1989-09-06 EP EP02009255.7A patent/EP1225168B8/en not_active Expired - Lifetime
-
1990
- 1990-05-04 FI FI902258A patent/FI92690C/fi active Protection Beyond IP Right Term
- 1990-05-04 DK DK199001121A patent/DK175842B1/da not_active IP Right Cessation
-
1992
- 1992-12-08 US US07/986,943 patent/US5422368A/en not_active Expired - Lifetime
-
1995
- 1995-02-16 US US08/390,394 patent/US5578618A/en not_active Expired - Lifetime
- 1995-06-05 US US08/461,334 patent/US5849791A/en not_active Expired - Lifetime
- 1995-06-06 US US08/470,607 patent/US5627208A/en not_active Expired - Lifetime
- 1995-06-21 HU HU95P/P00316P patent/HU211593A9/hu unknown
- 1995-09-20 JP JP7241200A patent/JP2955213B2/ja not_active Expired - Lifetime
-
1997
- 1997-08-04 JP JP20941997A patent/JP3612178B2/ja not_active Expired - Lifetime
- 1997-11-12 NL NL970039C patent/NL970039I2/nl unknown
-
1999
- 1999-05-10 US US09/307,814 patent/US6030999A/en not_active Expired - Fee Related
-
2000
- 2000-05-01 US US09/562,447 patent/US6429226B1/en not_active Expired - Fee Related
-
2003
- 2003-01-07 HK HK03100182.5A patent/HK1048106A1/zh unknown
- 2003-01-08 HK HK03100217.4A patent/HK1048251A1/zh unknown
-
2009
- 2009-03-11 LU LU91541C patent/LU91541I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK175842B1 (da) | Prostaglandinderivater til behandling af glaukom eller foröget okulært tryk | |
| US5296504A (en) | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | |
| US6417230B2 (en) | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | |
| WO1989003384A1 (en) | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | |
| CA1339132C (en) | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | |
| DK176053B1 (da) | Prostaglandinderivater til behandling af glaukom eller foröget okulært tryk | |
| NZ230619A (en) | Ophthalmological composition comprising a prostaglandin derivative for treating glaucoma | |
| EP1300151A2 (en) | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | |
| IE63250B1 (en) | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CTFF | Application for supplementary protection certificate (spc) filed |
Spc suppl protection certif: CA 2005 00041 Filing date: 20050922 Extension date: 20110718 |
|
| CTFG | Supplementary protection certificate (spc) issued |
Free format text: PRODUCT NAME: LATANOPROST Spc suppl protection certif: CA 2005 00041 Filing date: 20050922 |
|
| PUP | Patent expired |